This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (19) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ashton, C. H. Articles by Young, A. H. Search for Related Content PubMed PubMed Citation Articles by Ashton, C. H. Articles by Young, A. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Bipolar Disorder Hazardous Substances DB TETRAHYDROCANNABINOL Social Bookmarking                   What's this?

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential

P. B. Moore

P. Gallagher

A. H. Young

Department of Psychiatry, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition. No systematic studies of cannabinoids in bipolar disorder were found to exist, although some patients claim that cannabisrelieves symptoms of mania and/or depression. The cannabinoids ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD) may exert sedative, hypnotic, anxiolytic, antidepressant, antipsychotic and anticonvulsant effects. Pure synthetic cannabinoids, such as dronabinol and nabilone and specific plant extracts containing THC, CBD, or amixture of the two in known concentrations, are available and can be delivered sublingually. Controlled trials of these cannabinoids as adjunctive medication in bipolar disorder are now indicated.

Key Words: bipolar disorder • cannabidiol • cannabinoids • cannabis • CBD • depression • dronabinol • mania • nabilone • tetrahydrocannabinol • THC

Journal of Psychopharmacology, Vol. 19, No. 3, 293-300 (2005)
DOI: 10.1177/0269881105051541


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z. Atakan Cannabis use by people with severe mental illness - is it important? Advan. Psychiatr. Treat., November 1, 2008; 14(6): 423 - 431. [Abstract] [Full Text] [PDF]

				F. R. Bambico, N. Katz, G. Debonnel, and G. Gobbi Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex J. Neurosci., October 24, 2007; 27(43): 11700 - 11711. [Abstract] [Full Text] [PDF]

				P. D Skosnik Cannabis use increases risk of developing symptoms of mania Evid. Based Ment. Health, May 1, 2007; 10(2): 61 - 61. [Full Text] [PDF]

				S. M. Strakowski, M. P. DelBello, D. E. Fleck, C. M. Adler, R. M. Anthenelli, P. E. Keck Jr, L. M. Arnold, and J. Amicone Effects of Co-occurring Cannabis Use Disorders on the Course of Bipolar Disorder After a First Hospitalization for Mania Arch Gen Psychiatry, January 1, 2007; 64(1): 57 - 64. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]

				P. J. Zhu and D. M. Lovinger Ethanol Potentiates GABAergic Synaptic Transmission in a Postsynaptic Neuron/Synaptic Bouton Preparation From Basolateral Amygdala J Neurophysiol, July 1, 2006; 96(1): 433 - 441. [Abstract] [Full Text] [PDF]